Lewis Dyve

Dyve Announces Poster Presentation at 2023 AACR Annual Meeting

Retrieved on: 
Monday, April 17, 2023

Dyve Biosciences , Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that preliminary data from the ongoing pre-clinical partnership with the H. Lee Moffitt Cancer Center & Research Institute will be presented at a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place April 14-19, 2023, in Orlando, Florida.

Key Points: 
  • Dyve Biosciences , Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that preliminary data from the ongoing pre-clinical partnership with the H. Lee Moffitt Cancer Center & Research Institute will be presented at a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place April 14-19, 2023, in Orlando, Florida.
  • Dyve will present pre-clinical data from its lead oncology drug candidate, DYV800, a pH modulating agent that targets tumor microenvironment (TME) acidity in solid tumors.
  • “Dyve continues to advance research in areas where we believe our pH modulation program can achieve the biggest impact for patients and we look forward to sharing new pre-clinical data on our DYV800 program at this year’s AACR.
  • , Chief Executive Officer, Dyve.

Dyve Biosciences Appoints Tatyana Beldock to Board of Directors

Retrieved on: 
Tuesday, April 11, 2023

Dyve Biosciences, Inc. ("Dyve"), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that Tatyana Beldock has joined Dyve's Board of Directors.

Key Points: 
  • Dyve Biosciences, Inc. ("Dyve"), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that Tatyana Beldock has joined Dyve's Board of Directors.
  • , Chief Executive Officer of Dyve, stated: "We are thrilled to have Tatyana join our Board.
  • "Joining the Dyve Board of Directors is a wonderful opportunity to contribute to developing multiple breakthrough therapies for patients.
  • I'm excited to join the talented group of Dyve board directors and participate in this important work," said Ms. Beldock.

Dyve Biosciences to Participate in the BIO International Convention

Retrieved on: 
Wednesday, June 1, 2022

To register for the conference and schedule a one-on-one meeting with Dyve Biosciences management, please visit https://www.bio.org/events/bio-international-convention/registration .

Key Points: 
  • To register for the conference and schedule a one-on-one meeting with Dyve Biosciences management, please visit https://www.bio.org/events/bio-international-convention/registration .
  • BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide.
  • BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies.
  • Currently there are over 3,000+ international and domestic companies registered to attend BIO 2022 across the biotech industry.

Dyve Biosciences to Present at the UBS Global Healthcare Conference

Retrieved on: 
Wednesday, May 4, 2022

Please contact your UBS representative to schedule a one-on-one meeting with Dyve Biosciences management during the conference.

Key Points: 
  • Please contact your UBS representative to schedule a one-on-one meeting with Dyve Biosciences management during the conference.
  • Dyve is a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets,including acollection of new chemical entities (NCEs) in collaboration with a major pharmaceutical company.
  • Dyvestechnology includes a novel approach for delivering pH-adjusting agents through the skin.
  • This has the potential to decrease the acidic microenvironments that are key to the pathology and treatment of multiple disease states within oncology, immunology, and inflammation.

Dyve Biosciences to Present at the 34th Annual Roth Conference

Retrieved on: 
Wednesday, March 9, 2022

Roth Capital Partners, LLC (Roth) is a relationship-driven investment bank focused on serving emerging growth companies and their investors.

Key Points: 
  • Roth Capital Partners, LLC (Roth) is a relationship-driven investment bank focused on serving emerging growth companies and their investors.
  • As a full-service investment bank, Roth provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access.
  • Headquartered in Newport Beach, California, Roth is privately held and owned by its employees and maintains offices throughout the U.S. For more information on Roth, please visit www.roth.com .
  • Dyve is a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets,including acollection of new chemical entities (NCEs) in collaboration with a major pharmaceutical company.

Dyve Biosciences Announces the Appointment of Nicholas A. Saccomano, Ph.D., to its Scientific Advisory Board

Retrieved on: 
Tuesday, March 1, 2022

CAMARILLO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal drug delivery technology to a broad pipeline of clinical assets, today announced the appointment of Nicholas A. Saccomano, Ph.D., a seasoned biopharmaceutical professional with nearly 35 years of extensive research and development experience across multiple therapeutic areas, to lead its Scientific Advisory Board. Dr. Saccomano most recently worked at Pfizer R&D, Inc. as Chief Science Officer and Site Head at its Boulder facility, where he oversaw a 170-person team that advanced a portfolio of small-molecule drug programs from inception to proof-of-concept.

Key Points: 
  • Ryan Beal, M.D., CEO of Dyve, stated, Ive enjoyed getting to know Nick over the past year and am thrilled he is joining us in this new capacity.
  • In particular, his experience and expertise in drug delivery science and oncology drug development will be a tremendous asset to Dyve as we continue to advance our scientific and clinical assets.
  • Dyve is pioneering effective transdermal drug delivery for difficult-to-formulate molecules a potential game-changer for the pharmaceutical industry.
  • I look forward to working with the Dyve team to advance and exploit this powerful science.

Dyve Biosciences to Present at the Biocom California Global Life Science Partnering Conference

Retrieved on: 
Tuesday, February 22, 2022

The Lodge at Torrey Pines, San Diego, CA

Key Points: 
  • The Lodge at Torrey Pines, San Diego, CA
    For information about the Biocom Global Partnering Conference, and to register to meet with Dyve Biosciences management in-person or virtually, please refer to the conference website .
  • Dyve is a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets,including acollection of new chemical entities (NCEs) in collaboration with a major pharmaceutical company.
  • Dyvestechnology includes a novel approach for delivering pH-adjusting agents through the skin.
  • This has the potential to decrease the acidic microenvironments that are key to the pathology and treatment of multiple disease states within oncology, immunology, and inflammation.

Dyve Biosciences to Present at the 32nd Annual Oppenheimer Healthcare Conference

Retrieved on: 
Wednesday, February 16, 2022

Please contact your representative at Oppenheimer to schedule a virtual one-on-one meeting with Dyve Biosciences management during the conference.

Key Points: 
  • Please contact your representative at Oppenheimer to schedule a virtual one-on-one meeting with Dyve Biosciences management during the conference.
  • For information about the 32nd Annual Oppenheimer Healthcare Conference, please refer to the conference website .
  • Dyve is a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets,including acollection of new chemical entities (NCEs) in collaboration with a major pharmaceutical company.
  • This has the potential to decrease the acidic microenvironments that are key to the pathology and treatment of multiple disease states within oncology, immunology, and inflammation.

Dyve Biosciences Announces Research and Development Collaboration with Moffitt Cancer Center

Retrieved on: 
Thursday, February 3, 2022

CAMARILLO, Calif. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (Dyve), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets,today announced a joint, two-year research collaboration with Moffitt Cancer Center.

Key Points: 
  • CAMARILLO, Calif. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (Dyve), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets,today announced a joint, two-year research collaboration with Moffitt Cancer Center.
  • Dr. Gillies published pre-clinical research has shown that pH-adjusting agents can successfully modify the acidic microenvironment within tumors that allow cancer cells to evade treatment.
  • In 2015, Dr. Gillies and his colleagues published research demonstrating that systemic buffering increased the efficacy of checkpoint inhibitors in animal models of cancer.
  • Ryan Beal, M.D., Chief Executive Officer of Dyve, stated, This collaboration is a fortuitous convergence of Dr. Gillies long-standing, world-renowned research on the tumor microenvironment and the successful development of transdermal buffering agents at Dyve.

Dyve Biosciences Hosting Key Opinion Leader Webinar on Gout and DYV702

Retrieved on: 
Monday, November 15, 2021

Webinar to be held Tuesday, November 23rd @ 11am ET

Key Points: 
  • Webinar to be held Tuesday, November 23rd @ 11am ET
    THOUSAND OAKS, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (Dyve), a clinical stage biotechnology company,today announced that it will host a key opinion leader (KOL) webinar on gout on Tuesday, November 23, 2021 at 11:00am Eastern Time.
  • Both experts will discuss the current treatment landscape for gout and unmet medical need in treating the pain, swelling, and discomfort associated with gout flares.
  • DYV702 demonstrated a statistically significant improvement in overall response rate, lower rescue medication use, and an improvement in physical function.
  • Dyves lead asset, DYV702,recently completed a 20-center, 100-patient, Phase 2 clinical study for the treatment ofpainassociated with acute gout.